Clinical Trials on Nummular Dermatitis

Total 2990 results

Welcare Industries SpA

Recruiting

Clinical Trial to Evaluate Safety and Efficacy of Jalosome® Soothing Gel. (JALOSOME-01)

Radiation-induced Dermatitis

Italy
Medical University of Graz

Recruiting

Skin Microbiome and Polymorphic Light Eruption (PLE_microbio)

Polymorphic Light Eruption

Austria
Herbarium Laboratorio Botanico Ltda

Completed

Dermatological Assessment of Primary Dermal Irritability Accumulated and Sensitization of Hyaluronic Nasal Spray

Sensitivity, Contact

Brazil
Pfizer

Completed

Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis

Stasis Dermatitis

United States
Herbarium Laboratorio Botanico Ltda

Completed

Dermatological Assessment of Primary Dermal Irritability Accumulated and Sensitization

Sensitivity, Contact

Brazil
UNION therapeutics

Completed

Sensitization Study of ATx201 in Healthy Volunteers

Sensitivity, Contact

United States
Medical University of Graz
Austrian Science Fund (FWF)

Terminated

Vitamin D Supplementation in Polymorphic Light Eruption (VitD-PLE_2012)

Polymorphic Light Eruption

Austria
Medical University of Graz

Completed

Sunscreen and After-sun-lotion Protection in Polymorphic Light Eruption

Polymorphic Light Eruption

Austria
Massachusetts General Hospital

Active, not recruiting

Pilot Study of the Effect of Laser on Reversing Chronic Radiation Injury

Chronic Radiation Dermatitis

United States
Istanbul Bilgi University
Istanbul University - Cerrahpasa (IUC)

Enrolling by invitation

Effects of Critical Patient-centered Skin Care Protocol

Pressure Injury | Incontinence-associated Dermatitis

Turkey
Sanofi

Recruiting

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Monotherapy Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (ESTUARY)

Dermatitis Atopic

United States
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

Dermatitis Atopic

Argentina, Japan, China, Czechia, Spain, United States, South Africa, United Kingdom, Denmark, Sweden, Turkey
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis (PELISTAD-EX2)

Dermatitis Atopic

United States, United Kingdom
Sanofi

Recruiting

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (ATLANTIS)

Dermatitis Atopic

Italy, United Kingdom, Argentina, France, Chile, Czechia, Germany, Japan, Spain, China, Netherlands, Brazil, Canada, Denmark, Korea, Republic of, South Africa, Taiwan, Poland, India, Mexico
Sanofi

Recruiting

A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)

Dermatitis Atopic

United States
Sanofi

Recruiting

Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD)

Dermatitis Atopic

Norway, Spain, Argentina, Israel, Greece, United States, Australia, Brazil, Canada, China, Colombia, Denmark, France, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Portugal, Russian Federation
Sanofi
Regeneron Pharmaceuticals

Completed

Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis (PELISTAD)

Dermatitis Atopic

United States, United Kingdom
Azidus Brasil

Withdrawn

Efficacy and Safety of the Association Drugs in Patients With Allergic Dermatitis

Dermatitis

Brazil
GlaxoSmithKline

Completed

A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis

Skin Diseases

China
LEO Pharma

Completed

LEO 29102 Single and Multiple Dose Study by Dermal Application

Atopic Dermatitis

United Kingdom
Scotiaderm

Not yet recruiting

Efficacy of Cream for Moisture Associated Skin Damage From Fecal Incontinence and/or Diarrhea (Survey)

Incontinence-associated Dermatitis | Moisture Associated Skin Damage (MASD) (E.G., Incontinence-Associated Dermatitis [IAD], Perspiration, Drainage) | Fecal Incontinence Incontinence-associated Dermatitis
Vanda Pharmaceuticals

Completed

Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis

Treatment-resistant Pruritus Associated With Atopic Dermatitis

Germany
University of Maryland, Baltimore
Integra LifeSciences Corporation

Completed

MediHoney for Radiation Dermatitis

Breast Cancer | Radiation Dermatitis

United States
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids (SHORE)

Dermatitis Atopic

Japan, Chile, Canada, Argentina, United States, Turkey, China
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 1)

Dermatitis Atopic

Israel, Chile, Australia, United States, France, Canada, Germany, Korea, Republic of, Taiwan, China
Sanofi

Recruiting

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo (HYDRO)

Dermatitis Atopic

Canada, United States
Centre Hospitalier Universitaire de la Réunion

Not yet recruiting

HYPNOsis in the Management of Atopic Dermatitis in Children and Teenagers (HypnoDA)

Dermatitis

Réunion
Sanofi

Recruiting

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials (RIVER-AD)

Dermatitis Atopic

Canada, United States, Australia, Bulgaria, Czechia, Germany, Hungary, Japan, Poland, Spain, Taiwan, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) (GLOBOSTAD)

Dermatitis Atopic

Spain, Czechia, Italy, Israel, Argentina, Australia, Austria, Belgium, Colombia, Finland, France, Greece, Japan, Kuwait, Mexico, Netherlands, Norway, Portugal, Russian Federation, Saudi Arabia, Taiwan, United Arab Emirates
Hordinsky, Maria K., MD

Terminated

Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients

Dermatitis

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis

Dermatitis

United States
Mayo Clinic

Active, not recruiting

Determining Molecular Drivers of Radiation Dermatitis

Breast Cancer

United States
Stiefel, a GSK Company
GlaxoSmithKline

Completed

STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%

Dermatitis, Seborrheic
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (AQUA)

Dermatitis Atopic

Chile, United Kingdom, United States, Canada, Turkey, Israel, Korea, Republic of
Sanofi

Recruiting

A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment (AD-BEASCUITS)

Dermatitis Atopic

Italy
Sanofi

Active, not recruiting

Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)

Dermatitis Atopic

Australia, United States, Argentina, Brazil, Canada, Colombia, France, Mexico, Netherlands
Pfizer

Completed

A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

Dermatitis Atopic

United States
DermaGen AB

Completed

A Randomized, Double-blinded Placebo-controlled Study to Investigate Antimicrobial Efficacy and Safety Following Topical Application of DPK-060

Atopic Dermatitis

Sweden
Eli Lilly and Company

Not yet recruiting

Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis

Atopic Dermatitis

United States
Oneness Biotech Co., Ltd.

Not yet recruiting

Evaluate Efficacy, Pharmacokinetics, and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis
Apogee Therapeutics, Inc.

Recruiting

A Study Evaluating APG777 in Atopic Dermatitis

Atopic Dermatitis

United States, Canada
AbbVie

Recruiting

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Atopic Dermatitis

United States
Instituto de Investigación Hospital Universitario...

Recruiting

Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models

Atopic Dermatitis

Spain
Technoderma Medicines Inc.
Therapeutics, Inc.

Recruiting

Study of TDM-180935 in Atopic Dermatitis Patients

Atopic Dermatitis

United States
Hangzhou Yirui Pharmaceutical Technology Co., Ltd

Not yet recruiting

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Eli Lilly and Company

Recruiting

A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

China, Korea, Republic of
Møreforsking AS
University of Manchester; Helse Møre og Romsdal HF; Epax Norway AS

Recruiting

Nutritional Study to Determine the Effect of Fish Oil on Atopic Dermatitis (CetoSkin)

Atopic Dermatitis

Norway
Tavotek Biotherapeutics

Recruiting

A Study of TAVO101 in Atopic Dermatitis Patients

Atopic Dermatitis

New Zealand
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis
Akeso

Not yet recruiting

A Phase II Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

China

3

Subscribe